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collated and analyzed descriptively. Results: The implementation of LED-guided 
drug picking significantly reduced near misses for wrong drug [7.18 ± 3.17 vs 2.71 ± 
1.36, p< 0.001] and wrong strength [3.47 ± 2.48 vs 1.82 ± 1.13, p= 0.02]. There was no 
significant difference in the frequency of picking near misses for wrong quantity 
[17.8 ± 9.88 vs 14.0 ± 4.64, p= 0.162]. Overall, there was a significant reduction in the 
frequency of total picking near misses [28.4 ± 13.2 vs 18.1 ± 5.44, p= 0.007]. Pharmacy 
staff’s acceptance towards LED-guided picking was generally positive with majority 
preferring the LED over no LED-guided drug picking. ConClusions: Incorporation 
of LED into drug picking significantly decreased near misses of wrong drug and 
strength that potentially prevented costly medication errors. Pharmacy staff were 
generally receptive to LED-guided picking.
PHP249
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objeCtives: The aim of this review was to assess the critiques highlighted by the 
ERG for SR submitted to NICE by manufacturers as part of STA or MTA. Methods: 
ERG reports available on the NICE website were systematically searched for the 
last three years (2013-2015). The ERG comments in the documents were care-
fully assessed along with the submission documents. Emphasis was placed on 
ERG comments regarding search strategy design, electronic databases used for 
article retrieval, inclusion/exclusion criteria in SR, and reporting of SR methodol-
ogy. Results: Fourteen ERG comment documents were identified by the search 
conducted in May 2015. Ten documents were identified in 2013, three in 2014, and 
one in 2015. Comments on search strategies, such as incorrect search terms, miss-
ing terms, and wrong explosion, were made on seven submissions. Major findings 
such as chances of omission of key studies, missing intervention synonyms, and 
improper presentation of search strategies were cited in two submissions. Two sub-
missions did not search the minimum number of electronic databases indicated 
by NICE. ERG comments around SR inclusion/exclusion criteria were ambiguity in 
the study selection criteria, omission of the intervention of interest, selection of 
inappropriate follow-up duration, introduction of additional exclusion criteria at a 
later stage, exclusion of studies based on sample size, a clinically irrelevant primary 
outcome, exclusion of non-English studies even in cases of data gaps, and exclusion 
of some geographical subgroups without rationale. The write-up of SR was inad-
equate in two submissions because of ambiguity around the number of reviewers 
at each stage, unclarity around second check of extracted data, poor reporting of 
methodology, and an incorrect study selection flowchart. ConClusions: The ERG 
findings demonstrate a gap in manufacturer’s search strategy design, rationale for 
inclusion/exclusion criteria, and writing-up of the SR methodology which has led 
to additional work while providing clarifications to NICE.
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objeCtives: The objective of this study was to analyze the influence and develop-
ment of 13 HTA bodies in select Emerging Markets. Methods: This study examined 
13 HTA bodies in Latin America (Argentina, Brazil, Colombia, and Mexico), Asia (Korea, 
Taiwan, China, Singapore, Malaysia, and Thailand), Africa (South Africa), Middle East 
(Saudi Arabia), as well as Central and Eastern Europe (Turkey). The countries were 
selected based on the diversity associated with the HTA evaluation process, and 
were assessed for their review timeline, influence on the pricing and reimbursement 
process, and anticipated future developments as indicated from their websites and 
other publications. Results: Among the 13 selected HTA bodies, five countries (KOR, 
TWN, BRA, TUR, and ARG) have a defined review timeline; assessment outcomes 
will generally become available within a 1-year of submission. However, a standard 
timeline has yet to be defined for the rest of the countries. Four countries (KOR, TWN, 
BRA, and MEX) have formal HTA bodies, and assessments are mandatory in the pric-
ing and reimbursement process. In other six countries (SGP, ARG, COL, THA, SAU, 
and TUR), HTA assessments may be considered in the pricing and reimbursement 
evaluation. For CHN / MYS / ZAF, although an HTA body is under development, it does 
not currently have any impact on the reimbursement decision-making. For future 
HTA developments, the focus remains on scope expansion, capability building, and 
international collaboration. ConClusions: Emerging markets have developed or are 
in the process of developing HTAs for the evaluation of formulary inclusion and as a 
method of cost containment. The HTA bodies in the selected emerging markets have 
varying impact over the pricing and reimbursement process. The ones with greater 
influence tend to have a defined review timeline and an HTA body that is a formal 
authority with a mandatory and / or influential assessment.
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objeCtives: This study was designed to understand consumer likelihood to adopt 
a mobile application designed to allow individuals to view their personal health 
record on a mobile device as a function of risk tolerance of private medical data 
leaks, including variability by various demographics. Methods: A representative 
(U.S.) sample of 1,000 adults completed an online survey about their interest in an 
EHR mobile application. Interest in the application was elucidating using a 7-point 
Likert scale and a standard gamble (SG) exercise. The multivariate relationship 
between overall likelihood of mobile application use and SG utilities, education level, 
age, income level, and satisfaction with personal physician was assessed. Results: 
impact of the HTA system will be revealed by the number of drugs recommended 
that are subsequently placed on the reimbursement list, and with what restrictions.
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objeCtives: Health technology assessment (HTA) agencies generally prefer the 
submission of direct evidence when appraising new interventions; however, an 
absence of head-to-head trial data is relatively common and indirect comparison 
is often required to determine relative effectiveness. To inform future submissions, 
acceptance rates across six HTA agencies were compared between submissions 
presenting direct evidence (active-comparator studies) and submissions lacking 
direct evidence. Methods: All single HTA appraisals from 2014 for NICE (England), 
SMC (Scotland), CADTH (Canada), PBAC (Australia), IQWIG (Germany), and HAS 
(France) were included in the analysis, including resubmissions. Multiple technology 
appraisals, vaccination programmes, requests for advice, and submissions where 
the clinical evidence base was not described were excluded. The recommenda-
tion, reasoning behind the recommendation, and type of evidence presented were 
extracted. Fisher’s exact test was used to test for statistical significance. Results: 
In 2014, NICE accepted 92% (11/12) of all submissions presenting direct evidence 
versus 88% (7/8) of submissions lacking direct evidence, SMC accepted 79% (26/33) 
versus 87% (13/15), CADTH accepted 90% (9/10) versus 53% (10/19), PBAC accepted 
50% (26/52) versus 82% (14/17), IQWIG accepted 48% (13/27) versus 13% (2/15), and 
HAS accepted 97% (42/43) versus 92% (35/38). A lack of direct evidence tended to 
be acceptable in cases where hard endpoints could be compared, and in disease 
areas with small patient numbers or a lack of therapeutic alternatives. Adjusted 
indirect comparisons were generally favoured over unadjusted comparisons, where 
presented. ConClusions: With the exception of IQWiG (p= 0.025), acceptance rates 
for submissions reporting direct evidence were not significantly different to rates 
for submissions lacking direct evidence for each agency, although acceptance rates 
varied across HTA agencies. Single-arm or placebo-controlled trials continue to 
be viewed as acceptable clinical evidence by most HTA agencies when such study 
designs are justifiable, and when relative efficacy can be demonstrated through 
robust indirect comparison.
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objeCtives: We aimed to quantitatively segment the health technology assessment 
(HTA) agencies into functional archetypes to sort countries with similar functional 
objectives and process into one group. Methods: Through literature search, we 
developed a Likert scale comprising 77 question from 18 best practice principles, and 
6 functional domains. Each question is marked on a scale of 0-5, with higher score 
(4 or 5) indicating best practice/ease of accession and low score (0 or 1) indicating 
lack of guidance/difficulty in accession. Our scale includes the key attributes of HTA 
process, i.e. general submission process, pharmacoeconomics, pricing, and evidence 
requirements under six functional domains: transparency, process, technical, equity, 
speed and implementation. Results: We evaluated HTA guidelines and process 
of 66 HTA agencies worldwide, followed by scoring and weighted analysis. Using 
univariate analysis on total weighted score, we segregated the dataset into five 
percentiles, with definition reflecting functional objectives: 0-25% (Price Managers), 
26-50% (Formulary Managers), 51-75% (Cost Advisors), 76-90% (Value Appraisers), 
and 91-100% (Value Implementers). Characteristically, Price Managers (eg. Singapore, 
India, Hong Kong) are free pricing markets, where setting drug price is the only hur-
dle in market access. Formulary Managers (eg. US, China) control drug price based 
on budget and regulatory approval. Cost Advisors (eg. Brazil, Mexico) are emerging 
HTA agencies that use HTA to advice cost. Value Appraisers (eg. South Korea, New 
Zealand) perform HTA on regular basis, but regional requirements overcome imple-
mentation of findings to drug price and reimbursement. Value implementers (eg. 
England, Canada, Germany) are the most mature markets, with pay for performance 
measures being the primary functional objective. ConClusions: Our analysis pro-
vides a new approach to quantitatively benchmark and group HTA agencies into 
archetypes based on functional objectives and local priorities. Analysis at domain 
and principle level helps mapping the similarity of requirements by each archetype, 
enabling evidence-based launch planning.
PHP248
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objeCtives: Medication errors may occur during the drug picking process whereby 
the wrong drug, strength or quantity is picked. In May 2012, LED were installed 
and tagged to drug bins at the outpatient pharmacy in Singapore General Hospital 
with the intent to prevent these costly errors. Upon scanning a Quick Response 
(QR) code on the drug label, the LED corresponding to the drug bin will light up, 
signaling the picker to the correct drug bin. This study seeks to evaluate the safety 
impact of LED-guided drug picking and pharmacy staff’s acceptance of this sys-
tem. Methods: The primary outcome of this study is the safety of the drug picking 
process measured in terms of the frequency of picking near misses. Near miss data 
before (January to April 2012) and after (May to August 2012) implementation of 
LED-guided drug picking were extracted electronically for statistical comparison. 
A survey was administered on pharmacy staff (n = 50) to find out their accept-
ance on drug picking with and without LED-guidance. Data from the survey were 
